$5.10
3.04% yesterday
Nasdaq, Jun 11, 10:06 pm CET
ISIN
IE00B91XRN20
Symbol
PRTA
Sector
Industry

Prothena Corp. Plc Stock price

$5.10
-2.51 32.98% 1M
-9.05 63.96% 6M
-8.75 63.18% YTD
-15.39 75.11% 1Y
-4.86 48.80% 5Y
-41.25 89.00% 10Y
-2.10 29.17% 20Y
Nasdaq, Closing price Wed, Jun 11 2025
-0.16 3.04%
ISIN
IE00B91XRN20
Symbol
PRTA
Sector
Industry

Key metrics

Market capitalization $274.52m
Enterprise Value $-143.42m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.10
EV/Sales (TTM) EV/Sales -1.04
P/S ratio (TTM) P/S ratio 1.99
P/B ratio (TTM) P/B ratio 0.63
Revenue growth (TTM) Revenue growth 54.52%
Revenue (TTM) Revenue $137.94m
EBIT (operating result TTM) EBIT $-138.61m
Free Cash Flow (TTM) Free Cash Flow $-130.60m
Cash position $417.94m
EPS (TTM) EPS $-2.04
P/E forward negative
P/S forward 8.01
EV/Sales forward negative
Short interest 15.43%
Show more

Is Prothena Corp. Plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,842 stocks worldwide.

Prothena Corp. Plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Prothena Corp. Plc forecast:

4x Buy
44%
4x Hold
44%
1x Sell
11%

Analyst Opinions

9 Analysts have issued a Prothena Corp. Plc forecast:

Buy
44%
Hold
44%
Sell
11%

Financial data from Prothena Corp. Plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
138 138
55% 55%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 67 67
3% 3%
49%
- Research and Development Expense 209 209
13% 13%
152%
-138 -138
36% 36%
-100%
- Depreciation and Amortization 0.90 0.90
4% 4%
1%
EBIT (Operating Income) EBIT -139 -139
36% 36%
-100%
Net Profit -110 -110
36% 36%
-80%

In millions USD.

Don't miss a Thing! We will send you all news about Prothena Corp. Plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Prothena Corp. Plc Stock News

Neutral
Business Wire
20 days ago
DUBLIN--(BUSINESS WIRE)--Prothena today announced the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis did not meet its primary endpoint.
Neutral
Business Wire
about one month ago
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today reported financial results for the first quarter of 2025 and provided business highlights.
Neutral
Business Wire
about one month ago
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025.
More Prothena Corp. Plc News

Company Profile

Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Head office Ireland
CEO Gene Kinney
Employees 163
Founded 1969
Website www.prothena.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today